Table III.
Oncological outcomes after TORS for supraglottic SCC.
| Author (year) | No. of cases | T1 | T2 | T3 | T4 | N0 | N+ | R+ | Adjuvant RT or CH or CH-RT | Mean FU time (months) | OS (months) | DSS/DFS (months) | Local control (months) | Regional control (months) | Distant control (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Olsen (2012) 35 | 9 | 0 | 5 | 3 | 1 | 4 | 5 | 0 | 6 (67%) | 26 | 66.7% (26m) | 87.5% (26m) | 100% (26m) | 87.5% (26m) | 100% (26m) |
| Mendelsohn (2012) 20 | 14 | NA | NA | NA | NA | NA | NA | 0 | 10 (71%) | 28 | 88.9% (24m) | 100% (24m) | NA | NA | NA |
| Ansarin (2013) 17 | 10 | 4 | 4 | 1 | 1 | 6 | 4 | 4 | 7 (70%) | 25 | 100% (25m) | 100% (25m) | 100% (25m) | 90% (25m) | 100% (25m) |
| Oysu (2013) 25 | 3 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 2 (67%) | 14 | 100% (14m) | 100% (14m) | 100% (14m) | 100% (14m) | 100% (14m) |
| Park (2013) 12 | 16 | 7 | 6 | 4 | 0 | NA | NA | 0 | 8 (50%) | 16 | 91% (16m) | NA | NA | NA | NA |
| Razafindranaly (2015) 18 | 84 | 29 | 46 | 9 | 0 | 54 | 30 | 8 | 63 (75%) | 14 | 98% (14m) | 98% (14m) | 98% (14m) | NA | NA |
| Karabulut (2018) 15 | 17 | 5 | 4 | 8 | 0 | NA | NA | 0 | 13 (76%) | 25 | 88% (25m) | 94% (24m) | NA | NA | NA |
| Doazan (2018) 23 | 122 | 44 | 62 | 16 | 0 | 62 | 60 | 8 | 63 (52%) | 60 | 86.9% (24m) 78.7% (60m) | 95.1% (24m) 94.3% (60m) | 94.3% (24m) 90.2% (60m) | 91.8% (24m) 87.7% (60m) | NA |
| Hans (2020) 27 | 75 | 23 | 40 | 5 | 0 | 41 | 34 | 4 | 26 (35%) | 60 | 80.2% (60m) | 94.3% (60m) | 93.2% (60m) | 89.2% (60m) | NA |
| NA: not available; RT: radiotherapy; CH: chemotherapy; FU: follow-up; OS: overall survival; DSS: disease-specific survival; DFS: disease-free survival. | |||||||||||||||